Home Medical Devices COPD And Asthma Devices Market Size, Global Outlook, Growth and Forecast to 2031

COPD And Asthma Devices Market

COPD And Asthma Devices Market Size, Share & Trends Analysis Report  By Product Type (Inhalers, Drug Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Soft Mist Inhalers (SMIs), Nebulizers, Compressor Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers), By Indication (Asthma, COPD), By Distribution Channel (Retail Pharmacies, Hospitals, Online Pharmacies) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRMD54246DR
Study Period 2019-2031 CAGR 5.1%
Historical Period 2019-2021 Forecast Period 2023-2031
Base Year 2022 Base Year Market Size USD 42.90 Billion
Forecast Year 2031 Forecast Year Market Size USD 67.13 Billion
Largest Market North America Fastest Growing Market Europe
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

The Global COPD and Asthma Devices Market was valued at USD 42.90 billion in 2022 and is projected to reach USD 67.13 billion by 2031, with a CAGR of 5.1 % during the forecast period 2023–2031.

COPD and asthma devices, also referred to as pulmonary drug delivery devices are used as a permanent treatment or rescue therapy for respiratory diseases and other related conditions. It is the most advanced method of drug administration because the drug is delivered directly to the lungs for a systemic effect. COPD and asthma hold significant market shares for respiratory diseases worldwide. Various drug delivery protocols, such as oral and parenteral delivery, are developed for treating COPD and asthma. In contrast to other conventional treatment options, the pulmonary drug delivery system is the most effective.

Market Dynamics

What are the Driving Factors for The Global COPD and Asthma Devices Market?

Long-term exposure to particulate air pollution is linked with increased mortality and morbidity. According to CDC, tobacco smoke was found to be the key factor in the progression and development of COPD in the U.S., although exposure to air pollutants near the workplace and home, respiratory infections, and genetic factors also play a key role. In developing regions, outdoor air quality plays a greater role in the progression and development of COPD than in developed regions. COPD was the third important cause of death among chronic lower respiratory disorders. For instance, according to the National Health Portal, COPD is estimated to be the third leading cause of death by 2020. In addition, according to the data published by the Global Asthma Report, in 2018, around 339 million people were affected by Asthma.

Further, according to the CDC, around 26 million Americans have asthma. During the next 20 years, the number of Americans with asthma is expected to grow by 10%. Furthermore, in accordance with CDC, the following groups were reportedly prone to COPD:

  • Geriatric population in the age group of 65–74 years
  • Non-Hispanic white population
  • The unemployed, retired population
  • People with low incomes
  • Divorced, separated, or widowed population
  • Former or current smokers
  • Population with a family history of asthma

In addition, Populations inhabiting poor-quality neighborhoods and homes, which lack adequate provision for sanitation, water, garbage removal, and drainage, are specifically susceptible to respiratory disorders such as COPD and asthma. The use of kerosene lights and portable stoves for heating and cooking results in the inhalation of particulates. This vulnerability can prolong the share of the underdeveloped region population, such as LAMEA regions, in the progression toward COPD and asthmatic conditions. Further, women and children are specifically prone to COPD and asthma as they deal with many indoor tasks. Women spend longer indoors than men and are at a higher risk of developing respiratory disorders. In developed and developing regions, people who smoke indoors endanger their family members and themselves. Thus, the rise in indoor pollution is likely to supplement the demand for COPD and asthma devices.

Also, Portable aerosol inhalers allow selective treatment for COPD and asthma, owing to their advantage of achieving high drug concentrations in the airway coupled with reduced systemic side effects by manually controlling the systemic drug levels. Portable β2-agonists (bronchodilators) offer rapid onset of action compared to oral delivery medications. Some drugs are only active with aerosol delivery. A portable aerosol drug delivery mechanism is a convenient and painless delivery option. However, training is required on the specific inhalation techniques for the proper usage of various types of portable inhaler devices, as a less-than-optimal technology may result in reduced drug delivery. These reasons are expected to drive global COPD and asthma device adoption rates.

What are the Restraints for The Global COPD and Asthma Devices Market?

COPD and asthma treatment are time-consuming and expensive, and the treatment cost is a major concern as there is no one-time solution to this problem. Globally, most of the asthmatic population is low-income; therefore, the high cost of the treatment creates a problem for them. For instance, according to the American Thoracic Society, the healthcare costs of asthma in the U.S. are estimated to total $300 billion over the next twenty years. In addition, the yearly cost of asthma in the U.S. is around $56 billion. Therefore, every year increase in cost for the treatment of asthma is expected to hamper the market growth.

What are the Future Opportunities for The Global COPD and Asthma Devices Market?

Smart inhalers manage breathing flow and data. The trend toward designing more intuitive Bluetooth-enabled smart devices drives patient engagement and adherence while increasing treatment effectiveness. Furthermore, next-generation inhalers in development incorporate digital interfaces to manage and adapt patients’ breathing patterns. These devices understand the way the patient is breathing and coach him/her to breathe at the appropriate rate. This is particularly relevant in pediatric or geriatric patients. Furthermore, the medical treatments did not always fulfill the goal of treating the lungs. Hence, the development of these devices aids in the specific and accurate delivery of medicaments in asthmatic conditions. Owing to these benefits, the adoption of these devices is likely to fuel the growth of the COPD and asthma devices market.

Also, Patent expiration of drugs is likely to be a key opportunity for the overall COPD and asthma devices market, as the entry of generic products in the U.S., Europe, and Japan is expected to reduce sales of branded drugs. However, the local and branded manufacturers are likely to show revenue growth owing to increased sales of their devices. The patent expiration on asthma/COPD drugs, such as the patent on the Diskus inhaler, expired in 2016. Advair's patent expiration is expected to open investment opportunities for strengthening pipeline portfolios to meet the rising drug/device demands. Further, local manufacturers are anticipated to show notable growth resulting in substantial market growth, owing to the patent expiry of major COPD and asthma drugs from 2018 to 2019 in seven major markets (the U.S., the UK, Italy, Spain, Germany, France, and Japan).

Regional Analysis

The global market for COPD and Asthma Devices has been segmented based on geography into North America, Europe, Asia Pacific, and LAMEA.

North America is projected to be the highest revenue-generating region in 2021. COPD is the third leading cause of death in North America, after cancer and cardiac diseases. Lifestyle habits and environmental factors are the major factors leading to the cause of COPD. In addition, cigarette smoking, air pollution, respiratory allergies, and genetic factors are some of the other factors responsible for COPD. The U.S. is the leading market for COPD devices, followed by Canada, owing to the technologically advanced market scenario of the U.S. Further, GlaxoSmithKline, Novartis, AstraZeneca, and 3M Heath Care are some of the key players for the North American COPD and asthma devices market. In the U.S., COPD was the third leading cause of death, after cancer and cardiac diseases in 2019. According to the Healthy People. Gov, in 2019, more than 25 million people in the U.S. had asthma. Whereas approximately 14.8 million adults have been diagnosed with COPD. Furthermore, according to the National Institute of Health Survey, women are more likely to suffer from COPD as compared to men. Nearly 6.7% of women and 5.2% of men were reported to be diagnosed with COPD in the U.S. More than 70% of Americans suffering from COPD are below the age of 65 years2018. COPD is often misdiagnosed as asthma, leading to inappropriate treatment. It can be prevented by medication but cannot be cured. Treatment can only control the symptoms and slow down disease progression. The treatment of COPD in the U.S. includes inhaled therapies, which include devices such as inhalers and nebulizers. The presence of these devices in the market and their effective usage boost the market for COPD devices in the U.S.

The European COPD and asthma devices market has witnessed rapid growth due to increased disease awareness, a rise in the patient pool of pediatric asthma and geriatric population susceptible to COPD, and the launch of new and innovative therapies. Further, MDIs contain chlorofluorocarbons (CFCs) as propellants, which deplete the ozone layer. Hence, regulatory approval for MDIs has become a major concern in the industry. The UK COPD and asthma devices market has witnessed steady growth due to factors such as an increase in the geriatric population, changing lifestyles, a rise in the number of tobacco smokers, environmental pollution, and upcoming innovative technologies. Novartis Ultibro Breezhaler was the first dual-action bronchodilator to be approved in the EU for the treatment of COPD. Ultibro Breezhaler combines the action of a long-acting muscarinic antagonist (LAMA) glycopyrronium bromide along with a long-acting beta-agonist (LABA) indacaterol, which are approved as monotherapies in the EU.

The Asia-Pacific accounted for the fastest-growing region in 2021. The Asia-Pacific COPD and asthma devices market includes countries such as India, China, Japan, and Australia, among others. The deaths that occurred due to COPD and asthma were around 90%, which is mostly in low- and middle-income level countries in the Asia-Pacific region. Further, India and China together accounted for almost 66% of the total global COPD mortality rate. An increase in awareness and per capita spending on healthcare services and a rise in incidence rate are expected to boost the growth of the Asia-Pacific COPD devices market. Consumers in the Asia-Pacific region prefer technologically advanced systems for the treatment of COPD, and this rate is expected to increase in the forthcoming years. According to the WHO, the COPD mortality rate is expected to increase rapidly in South East Asia. Drug treatments and surgeries are practiced in the Asia-Pacific countries, but the usage of medical devices for the treatment of COPD is an upcoming trend in the market. However, the adoption rate of such devices in the Asia-Pacific region exhibits lower than that of other regions. An increase in awareness among Asians about the usage and benefits of these devices and the affordability of medical devices are the key reasons for the significant growth of the COPD devices market. For instance, in 2019, Philips India launched an awareness campaign aiming to educate consumers about Asthma and help people manage their Asthma symptoms better. However, looking at the future scenario, the usage rate of COPD devices in the Asia-Pacific region is expected to increase rapidly.

The markets considered in this region include Latin America, the Middle East, and Africa. The growing geriatric population, rise in the prevalence of diseases and increase in industrial exhaust gases and automotive gases, among others, have fueled the incidence rate of COPD and asthma in the LAMEA region. Moreover, degrading air quality near industrial areas has resulted in a substantial increase in the incidence of COPD and asthma cases in low-income countries such as Brazil and Argentina. In addition, the rise in disposable income across developing regions, such as Latin America and the Middle East, has resulted in increased usage of asthma devices, such as inhalers and nebulizers, in this region. Latin American countries have their own independent approval processes; however, COPD and asthma devices may have FDA or European Commission approvals (CE mark). The documentation and approval time of these devices varies by country. A free sale certificate (FSC) or a certificate to a foreign government (CFG), both of which confirm that the product is approved in the country of origin and can be exported without restriction, is a prerequisite for Latin American registrations. The National Medicines Regulatory Authorities (NMRA), African Organization for Standardization (ARSO), and United Nations Economic Commission for Africa (UNECA) are the regulatory bodies in Africa. The UNECA has set standards and guidelines for medical devices used in COPD and asthma development, manufacture, quality control, and conformity assessment requirements.

COPD and asthma are the leading respiratory diseases globally. The COPD and asthma drug delivery system includes devices such as inhalers and nebulizers. The Latin American inhalers market accounts for more than 80% of the LAMEA COPD and asthma devices market. However, the nebulizer market constitutes a 13% share of the LAMEA COPD and asthma devices market. Inhalers occupy a significant market share due to their preferred usage over nebulizers and ease of portability. In addition, inhalers are widely used by adolescents and the geriatric population diagnosed with asthma or COPD symptoms in Latin America. Moreover, the rise in the approval rate of inhalers by key players in this region has boosted the growth of the COPD and asthma devices market in Latin America.

Report Scope

Report Metric Details
Segmentations
 By Product Type
  1. Inhalers
  2. Drug Powder Inhalers (DPIs)
  3. Metered Dose Inhalers (MDIs)
  4. Soft Mist Inhalers (SMIs)
  5. Nebulizers
  6. Compressor Nebulizers
  7. Ultrasonic Nebulizers
  8. Mesh Nebulizers
By Indication
  1. Asthma
  2. COPD
By Distribution Channel
  1. Retail Pharmacies
  2. Hospitals
  3. Online Pharmacies
Company Profiles Aerogen, Inc. AstraZeneca PLC Baxter International Inc. Boehringer Ingelheim International GmbH 3M COMPANY GF Health Products GlaxoSmithKline Plc Koninklijke Philips N.V. Novartis AG PARI Medical Holding GMBH Smith’s Group Plc.
Geographies Covered
North America U.S. Canada
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
APAC China Korea Japan India Australia Taiwan South East Asia Rest of Asia-Pacific
Middle East and Africa UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
LATAM Brazil Mexico Argentina Chile Colombia Rest of LATAM
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

The Global COPD and Asthma Devices Market are segmented based on Product Type, Indication, and Distribution Channel.

The market is segmented by types of devices into inhalers and nebulizers. These two devices are frequently used in the treatment of COPD and asthma.

Inhalers are small handheld devices that are used to deliver medicines for the treatment of chronic obstructive pulmonary disease. Presently, three types of inhalers are available in the market: dry powder inhalers, metered dose inhalers, and soft mist inhalers. In addition, inhalers are available in two forms, i.e., rescue inhalers and maintenance inhalers. The inhalation route is the fastest and most effective method of delivering medications to the respiratory system during the treatment of COPD and asthma. This type of treatment is known as combination therapy, in which a combination of two control medications is delivered through an inhaler. Further, innovations of new inhalers such as smart inhalers are an approach to promote adherence by monitoring medication use on the basis of respiratory disorders. It is also observed that there is a significant opportunity for smart inhalers to improve outcomes and reduce treatment costs. In clinical studies, 80% adherence to preventative medication has been observed among asthma patients using smart inhalers, with a 61% reduction in oral steroid use. Thus, the significant innovations and the use of inhalers in the market by respiratory patients resulted in the largest market share of the inhalers market.

Over the past few decades, physicians have widely used the corticosteroid inhalation technique. Nebulization is one of the common methods used to administer medical aerosol. Nebulizers are widely used by adults and children globally, particularly for the treatment of COPD and asthma. The easy-to-use delivery mechanism of nebulizers has significantly attracted children and geriatric patients who face difficulty using conventional inhalation devices such as DPIs and MDIs. Nebulizer converts liquid medication into a mist, which must be inhaled into the lungs. Nebulizers are portable devices; hence, they have wider acceptance in home healthcare. The device usually takes 20 minutes or less, depending upon the inhaled medication dosage. In addition, nebulizers and mouthpieces need to be cleaned with soap and water before its use. Soft mist inhalers and nebulizers are prescription-based products, while some bronchodilator inhalers, such as DPIs and MDIs, are sold over the counter.

The market is segmented by Indication into asthma and COPD.

Asthma is a respiratory disease that blocks the airways of the lungs due to inflammation. The major symptoms of asthma are coughing, wheezing, shortness of breath, and chest tightness. It may develop while exercising, called exercise-induced bronchoconstriction. Asthma majorly occurs in children below five years of age. Sometimes, a person with a history of asthma may suffer from allergic asthma. In addition, a person inhaling fumes, gases, or dust regularly might develop asthma. There is no cure for asthma, but it can be managed once diagnosed properly.

Chronic obstructive pulmonary disease is a progressive disease caused by damage to the lungs over many years, usually due to smoking or long-term exposure to chemical fumes or dust. It shows symptoms such as coughing with a large amount of mucus, wheezing, shortness of breath, chest tightness, and others. In addition, WHO stated that COPD is expected to be the third leading cause of death worldwide by 2030. At the same time, more than 90% of COPD deaths occur in low- and middle-income countries.

The market is segmented by Distribution channel into retail pharmacies, hospitals, and online pharmacies.

Retail pharmacies are preferred by the population, as it is the oldest and most conventional medium distributing respiratory devices to consumers, owing to their large chain distribution network of pharmacies store. Further, the pharmacist may play a relevant role in the primary and secondary prevention of cardiovascular diseases through patient education and counseling, drug safety management, medication review, monitoring and reconciliation, and detection and control of specific respiratory risk factors. Thus, these factors are attributed to offering significant opportunities for the COPD and asthma devices market during the forecast period.

Patients suffering from serious respiratory diseases are prescribed inhalers and nebulizers for asthma and COPD patients. The hospital pharmacies acquired the largest share in 2021 as the medications are often prescribed after a thorough diagnosis, which is often conducted at these hospitals. Thus, this increased the growth of hospitals for COPD and asthma devices.

Online pharmacies are virtual shopping portals where one can purchase goods and services via the internet. Online mode of shopping is convenient, provides services 24/7, offers a variety of products in one place, and offers the ability to compare prices. Based on the distribution channel, the online pharmacy segment is expected to grow at the highest rate during the forecast period, owing to the convenient shopping option for individuals to order COPD devices based on the prescription and get them delivered to their doorstep. In addition, global and local manufacturers are distributing their products through their distributors using the online medium. Hence, the availability of various asthma devices, such as inhalers and nebulizers available online, is more than the pharmacies/retail stores, which helps patients to buy products easily. This leads to market growth during the forecast period.

Market Size  By Product Type

Recent Developments

  • In Oct 2019, GlaxoSmithKline plc and Innoviva, Inc. filed a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) seeking an additional indication for the use of once-daily, single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI), for the treatment of asthma in adults. Trelegy Ellipta was approved in the U.S. in September 2017 for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).
  • In Dec 2018, AstraZeneca today announced that the European Commission (EC) had approved Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in a pressurized metered-dose inhaler (pMDI) as a maintenance dual bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)
  • In Nov 2018, GlaxoSmithKline plc and Innoviva, Inc. got a European Commission authorization to expand a label for Trelegy Ellipta, recognized as an effective exacerbation.
  • In Dec 2017, PARI Pharma GmbH, a company focused on developing and commercializing advanced aerosol delivery systems based on eFlow Technology, announced the approval of its first eFlow closed system nebulizer Magnair together with Sunovion's Lonhala (glycopyrrolate) Inhalation Solution.
  • In May 2017, Philips expanded its Sleep & Respiratory Care business with the acquisition of US-based RespirTech. A US-based provider of an innovative airway clearance solution for patients with chronic respiratory conditions, such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis.

Top Key Players

COPD And Asthma Devices Market Share of Key Players

Aerogen, Inc. AstraZeneca PLC Baxter International Inc. Boehringer Ingelheim International GmbH 3M COMPANY GF Health Products GlaxoSmithKline Plc Koninklijke Philips N.V. Novartis AG PARI Medical Holding GMBH Smith’s Group Plc.

Frequently Asked Questions (FAQs)

What is the estimated growth rate (CAGR) of the global COPD and asthma devices market?
The global market size is growing at a CAGR of 5.1% from 2023 to 2031.
North America has the largest share of the market.
increased mortality and morbidity is the key driver for the growth of the market.
Patent expiration of drugs is likely to be a key opportunity is one of the upcoming trend in the market.
The key players in the global COPD and asthma devices market include Aerogen, Inc., AstraZeneca PLC, Baxter International Inc., Boehringer Ingelheim International GmbH, 3M COMPANY, GF Health Products, GlaxoSmithKline Plc, Koninklijke Philips N.V., Novartis AG, PARI Medical Holding GMBH, Smith’s Group Plc.


We are featured on :